Skip to main content
Caplight Logo









Kernal Biologics

Kernal Biologics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://kernalbio.com

Last Round

Grant

Oct 7, 2025

Total Funding Raised

$25M

Company Overview

Kernal Biologics is a biotechnology company that develops mRNA-based immunotherapies for cancer and autoimmune diseases using AI-designed, cell-selective mRNA and targeted lipid nanoparticle technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, NLP & Conversational AI, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

mRNA therapeuticsmRNA designin vivo CAR-Tsolid tumor therapycomputational biologylarge language modelLLMdrug discoveryprecision medicinebiotech platformAI drug discoverymRNA 2.0biotech licensingAI for biologybio-pharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kernal Biologics Comparables

Compare Kernal Biologics with similar companies based on industry and business-model similarity.

Kernal Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RNAimmune
82%
Strand Therapeutics
81%
HelixNano
80%

Kernal Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 7, 2025
Series AJul 7, 2022

Kernal Biologics Investors

Notable investors and investment history

Kernal Biologics investors
InvestorRounds
Amino CollectiveSeries A
HBM Healthcare InvestmentsSeries A
Amgen VenturesSeries A
ARPA-HGrant
Civilization VenturesSeries A
Hummingbird VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Grew 19% QoQ, from 16 to 19 employees.

  • Oct 8, 2025

    KR-402 is in development for B cell cancers.

Kernal Biologics Filings

Explore SEC and related filing metadata, where available.

Kernal Biologics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kernal Biologics's valuation, stock price, and market status.

Is Kernal Biologics a public or private company?

Kernal Biologics is a private company.

What is the current stock price of Kernal Biologics?

Kernal Biologics is a private company, so its shares have no public market price. Caplight tracks Kernal Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Kernal Biologics worth (valuation)?

Valuation information for Kernal Biologics is not publicly available.

Can I buy Kernal Biologics stock?

Kernal Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Kernal Biologics's last funding round?

Kernal Biologics's most recent funding round was Grant on October 7, 2025.

Who are the main investors in Kernal Biologics?

Key investors in Kernal Biologics include Hummingbird Ventures.

Will Kernal Biologics IPO soon?

No public IPO plans have been announced for Kernal Biologics.

How can I track Kernal Biologics secondary market activity?

Caplight tracks bids, offers, and trades in Kernal Biologics's shares on secondary markets.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range13
Year Founded2016
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?